Hualan Biological Engineering Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hualan Biological Engineering Inc with three other
companies in this sector in China:
Beijing Tiantan Biologic.
sales of 1.62 billion Chinese Renmimbi [US$233.10 million]
Staidson (Beijing) Biopharmaceuticals Co Ltd
(1.25 billion Chinese Renmimbi [US$179.86 million]
of which 100%
was Pharmaceutical manufacturing), and
Tonghua Dongbao Medicines Company Limited
(1.67 billion Chinese Renmimbi [US$240.33 million]
of which 97%
Hualan Biological Engineering Inc reported sales of 1.47 billion Chinese Renmimbi (US$211.91 million)
December of 2015.
increase of 18.3%
versus 2014, when the company's sales were 1.24 billion Chinese Renmimbi.
This was the fourth straight year of sales growth at Hualan Biological Engineering Inc.
Sales of Blood Products saw an increase
26.4% in 2015, from
1.07 billion Chinese Renmimbi to 1.35 billion Chinese Renmimbi.
Not all segments of Hualan Biological Engineering Inc experienced an increase in sales in 2015:
sales of Other Operations fell 47.1% to 6.58 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Hualan Biological Engineering Inc also experienced decreases in sales in
Vaccine Products (down 30.6% to 111.17 million Chinese Renmimbi)